



Buyback programme

On 19 August 2016, Ambu initiated a parallel share buyback programme for totalling up to 268,000 B-shares. The purpose of the programme is to hedge share-based incentive programmes.

Under the programme, the remaining transactions - as shown in the overview below - were conducted in the period 19 to 27 September 2016. Consequently the share buyback programme is now concluded having bought a total number of 268,000 shares at a price of DKK 88.0m in total since 19 August 2016:

| Date | Number of B shares | Average market price | Transaction value |
|---------------------------------|--------------------|----------------------|-------------------|
| Accumulated latest announcement | 230,400 | 327.2 | 75,386,242 |
| 19 September 2016 | 13,000 | 328.9 | 4,275,343 |
| 20 September 2016 | 5,000 | 325.3 | 1,626,536 |
| 21 September 2016 | 3,000 | 337.1 | 1,011,315 |
| 22 September 2016 | 5,000 | 340.8 | 1,704,002 |
| 23 September 2016 | 4,000 | 340.3 | 1,361,159 |
| 26 September 2016 | 5,100 | 340.3 | 1,735,324 |
| 27 September 2016 | 2,500 | 343.9 | 859,738 |
| Accumulated under the programme | 268,000 | 328.2 | 87,959,659 |

Following the above transactions, Ambu owns a total of 1,365,472 Class B shares with a nominal value of DKK 2.82 each, corresponding to 2.5% of the share capital. The total number of Class A and Class B shares in the company is 48,370,720 including treasury shares.

Contact

Lars Marcher, President & CEO, tel. +45 5136 2490, email: lm@ambu.com

About Ambu

Since 1937, breakthrough ideas have fuelled our work on bringing efficient healthcare solutions to life. This is what we create within our fields of excellence – Anaesthesia, Patient Monitoring & Diagnostics, and Emergency Care. Millions of patients and healthcare professionals worldwide depend on the functionality and performance of our products. We are dedicated to improve patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu Bag™ resuscitator and the legendary BlueSensor™ electrodes to our newest landmark solutions like the aScope™ endoscope – the world's first single-use flexible video scope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognized medical companies in the world. Headquartered near Copenhagen in Denmark, Ambu employs approximately 2,300 people in Europe, North America and the Asia Pacific. For more information, please visit www.ambu.com.